Clear clinical remission of a diffuse metastasized ovarian clear cell carcinoma with third line chemotherapy

Historical control study of paclitaxel–carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer

“…In our cases at stage III-IV the response rate was 86.8%, and was highest in the TJ serous group. Previous reports [11][12][13] had indicated that the TJ regimen was scarcely effective for clear cell adenocarcinoma and mucinous adenocarcinoma. However, we observed a response in 40% (2/5) of our clear cell adenocarcinoma cases and in all three mucinous adenocarcinoma cases (data not shown).…”